FDA Approves Lilly's Foundayo Oral Obesity Pill; Immunovant Batoclimab Fails Phase 3 TED Trials

The FDA just approved the first oral GLP-1 pill for obesity — Eli Lilly's Foundayo — and Lilly shares jumped nearly four percent on the news.

Immunovant's batoclimab struck out in both Phase 3 thyroid eye disease trials, the White House is reportedly drafting hundred-percent tariffs on imported brand-name drugs, and three PDUFA dates land before the weekend. Wednesday came to play.

Welcome to The Pharma Closeout for Wednesday, April first, twenty twenty-six. I'm Alex Mercer.

And I'm Maya Patel.

Foundayo. That's the brand name for orforglipron — Lilly's once-daily oral GLP-1 receptor agonist — and as of today, it has FDA approval for obesity. Lilly closed at nine fifty-four fifty-two, up three point seven eight percent, market cap now at eight hundred fifty-four point three billion dollars. This is the stock's biggest single-day move in months, and the reason is obvious — Lilly just made the obesity market accessible to every patient who refused to pick up a needle.

The approval pathway is worth flagging. This came through the FDA's Commissioner's National Priority Voucher program, which has drawn real criticism for how it prioritizes certain applications over the standard review queue. Whether you think that mechanism is good policy or a shortcut, the commercial reality is the same — an oral pill removes the injection barrier, and that changes who initiates therapy. Not just willingness. Adherence patterns shift completely when you move from a weekly injection to a daily pill.

And the competitive fallout for Novo Nordisk is immediate. Novo has Wegovy dominating on the injectable side and its own oral semaglutide still in development. Lilly planted the flag first. The strategic question: does oral convenience displace injectable market share directly, or does it pull in an entirely new patient population that was never going to inject?

It's not either-or, but the expansion effect dominates near-term. There is a substantial population that has resisted GLP-1 therapy purely on route of administration. Oral access brings them into the treatable universe. But here's where I'd push back on the euphoria — the approval gets Foundayo to market. It doesn't tell us how the weight-loss magnitude stacks up against injectable comparators in real-world adherence settings. Pivotal trial data earns the label. Head-to-head commercial positioning is where this actually gets decided over the next twelve to eighteen months.

That's fair. But Lilly has a second advantage people are underweighting — manufacturing scale. They've committed over fifty billion dollars in U.S. manufacturing investment since twenty-twenty. An oral small molecule is inherently simpler to produce at volume than a peptide injection. If demand spikes — and the early indicators suggest it will — Lilly has the capacity story to match the demand story. That supply bottleneck that plagued the injectable rollouts? Much less likely here.

Which is precisely why Novo has to accelerate its own oral timeline. Every mid-cap with a GLP-1 asset woke up this morning to a higher bar. Oral isn't aspirational anymore — it's FDA-approved and headed to pharmacy shelves. The competitive clock in obesity just got significantly faster for everyone chasing this space.

The deal flow didn't slow down for Foundayo headlines. Merck signed an antibody discovery collaboration with Infinimmune, a California-based startup. Per the company's announcement, the deal could reach eight hundred thirty-eight million dollars in upfront and milestone payments. Merck is licensing access to Infinimmune's human-first antibody discovery platform to develop candidates across multiple disease targets. This is Merck systematically diversifying its discovery engine — bringing in external technology rather than building everything internally.

On the capital formation side — Blackstone closed a six point three billion dollar life sciences fund. Nearly forty percent larger than its predecessor vehicle.

That's being reported as the largest life sciences private fund ever raised. Six point three billion in a single vehicle tells you where institutional money sees the highest risk-adjusted returns over the next cycle. That capital will concentrate in mid-stage clinical assets where private investors can underwrite the derisking event and capture the valuation step-up. For smaller biotechs approaching Phase 2 readouts, the fundraising environment just got meaningfully easier.

Quick hits on the rest. Cyclerion Therapeutics surged three hundred fifty percent on a reverse merger with Korsana Biosciences — a Paragon Biosciences offshoot focused on Alzheimer's — stock went from a dollar fifty-five to six ninety-eight overnight. Cogent Biosciences filed its NDA for bezuclastinib in GIST under real-time oncology review, backed by Phase 3 PEAK data: sixteen point five months median PFS and a forty-six percent overall response rate in imatinib-resistant patients. Zai Lab announced a clinical trial collaboration with Amgen — they'll evaluate Zai's DLL3-targeting ADC combined with Amgen's IMDELLTRA in extensive-stage small cell lung cancer.

And two pipeline setbacks to note: Gilead terminated a Phase 2/3 trial of long-acting oral HIV pills following an earlier clinical hold, and Alto Neuroscience shelved its schizophrenia cognitive impairment program after a Phase 2 miss.

The Cogent NDA is the one that matters most in that stack. Bezuclastinib carries Breakthrough Therapy designation, real-time oncology review gives it an accelerated clock, and a sixteen point five month median PFS in imatinib-resistant GIST would meaningfully change the second-line treatment sequence. If the label holds, oncologists get a credible new option in a space that has been starved for one.

On the regulatory side — Immunovant's batoclimab missed the primary endpoint in both Phase 3 thyroid eye disease studies. Safety was clean, consistent with prior data, no new signals. But the dosing architecture is what sank this. Patients showed greater proptosis improvement during the initial twelve-week high-dose period than during the subsequent twelve-week low-dose period. The step-down couldn't sustain the IgG trough suppression needed to hold the response — essentially, they backed off the gas precisely when the biology demanded they keep their foot down.

So the mechanism worked, but the dose regimen didn't. What does that mean for the broader FcRn competitive landscape?

It validates FcRn inhibition as a viable approach in TED while exposing that sustained deep IgG suppression is non-negotiable for durable efficacy. Immunovant is pivoting to IMVT-fourteen-oh-two for Graves' disease, with pivotal data expected in twenty twenty-seven. Meanwhile, argenx and Vyvgart continue to consolidate the autoimmune FcRn space without a serious clinical challenger. This trial failure doesn't close the door on FcRn in ophthalmology — it just proves that underdosing the biology to manage the tolerability profile is the wrong trade-off.

Also worth noting on the regulatory front — STAT News reports the Trump administration is preparing potential hundred-percent tariffs on certain imported brand-name pharmaceuticals. European-headquartered manufacturers — Novo Nordisk, AstraZeneca, Roche, Sanofi — carry the most direct exposure. Separately, Vertex won expanded labeling for its cystic fibrosis medicines, Caribou Biosciences received RMAT designation for CB-oh-eleven, its allogeneic CAR-T candidate, and the FDA delayed its decision on Orca Bio's cell therapy for blood cancers.

The UK's NICE also cleared Wegovy for cardiovascular risk reduction — a label Novo has been pursuing globally. And Novo cut four hundred jobs in Indiana tied to a manufacturing facility. But the tariff signal dwarfs all of that. If the White House follows through on hundred-percent duties, every global pharma company with a European manufacturing footprint needs to recalculate its U.S. pricing and supply chain architecture. That's not a hypothetical policy discussion — that's a scenario CFOs should be modeling this week.

Looking ahead — three PDUFA dates in the next six days. April third, nusinersen high-dose. April fifth, tividenofusp alfa. April seventh, the PADCEV plus KEYTRUDA combination. That last one carries the largest commercial footprint by far — a potential first-line standard-of-care shift in urothelial carcinoma.

The PADCEV-KEYTRUDA decision is what institutional investors are circling on the calendar. If the label lands as broadly as the EV-302 data supports, it doesn't just add a regimen — it reorders frontline bladder cancer treatment and pulls significant revenue into the combination franchise. That's the kind of approval that reshapes competitive positioning across an entire tumor type.

We'll also be tracking follow-through on AstraZeneca's EMERALD-3 results — positive Phase 3 data for the Imfinzi-Imjudo combination in liver cancer. The headline was encouraging. The full data package will determine whether that translates into a real threat to the current treatment paradigm — or just another positive readout that doesn't change practice.

That's your Pharma Closeout for Wednesday. Foundayo reshaping the oral obesity race, Immunovant regrouping after a double Phase 3 miss, Blackstone putting six point three billion behind biopharma's next cycle, and tariff threats hanging over imported drugs. If this briefing saves you time, follow us on Spotify and drop a rating — it genuinely helps us reach more people in this industry. We'll be back tomorrow.

Go enjoy your evening. See you tomorrow. ### Episode Metadata **Title:** FDA Approves Lilly's Foundayo Oral Obesity Pill; Immunovant Batoclimab Fails Phase 3 TED Trials; Trump Eyes 100% Drug Import Tariffs | Apr 01, 2026 **Description:** Lilly's Foundayo becomes the first oral GLP-1 approved for obesity in the U.S. — LLY jumps 3.78%. Immunovant's batoclimab misses both Phase 3 endpoints in thyroid eye disease. Plus: Merck-Infinimmune $838M antibody deal, Blackstone's record $6.3B life sciences fund, and the White House readies 100% tariffs on imported brand-name drugs. **Tags:** Foundayo, orforglipron, Eli Lilly, obesity, GLP-1, oral obesity pill, FDA approval, Immunovant, batoclimab, thyroid eye disease, FcRn, Merck, Infinimmune, Blackstone, Cogent Biosciences, bezuclastinib, GIST, Cyclerion, Korsana, Novo Nordisk, Wegovy, PADCEV, KEYTRUDA, drug tariffs, pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals #